Journal of General Internal Medicine

, Volume 31, Issue 8, pp 878–887 | Cite as

Does Motivation Matter? Analysis of a Randomized Trial of Proactive Outreach to VA Smokers

  • Elisheva R. Danan
  • Anne M. Joseph
  • Scott E. Sherman
  • Diana J. Burgess
  • Siamak Noorbaloochi
  • Barbara Clothier
  • Sandra J. Japuntich
  • Brent C. Taylor
  • Steven S. Fu
Open Access
Original Research



Current guidelines advise providers to assess smokers’ readiness to quit, then offer cessation therapies to smokers planning to quit and motivational interventions to smokers not planning to quit.


We examined the relationship between baseline stage of change (SOC), treatment utilization, and smoking cessation to determine whether the effect of a proactive smoking cessation intervention was dependent on smokers’ level of motivation to quit.


Secondary analysis of a multicenter randomized controlled trial.


A total of 3006 current smokers, aged 18–80 years, at four Veterans Affairs (VA) medical centers.

Interventions: Proactive care included proactive outreach (mailed invitation followed by telephone outreach), offer of smoking cessation services (telephone or face-to-face), and access to pharmacotherapy. Usual care participants had access to VA smoking cessation services and state telephone quitlines.

Main Measures

Baseline SOC measured with Readiness to Quit Ladder, and 6-month prolonged abstinence self-reported at 1 year.

Key Results

At baseline, 35.8 % of smokers were in preparation, 38.2 % in contemplation, and 26.0 % in precontemplation. The overall interaction between SOC and treatment arm was not statistically significant (p = 0.30). Among smokers in preparation, 21.1 % of proactive care participants achieved 6-month prolonged abstinence, compared to 13.1 % of usual care participants (OR, 1.8 [95 % CI, 1.2–2.6]). Similarly, proactive care increased abstinence among smokers in contemplation (11.0 % vs. 6.5 %; OR, 1.8 [95 % CI, 1.1–2.8]). Smokers in precontemplation quit smoking at similar rates (5.3 % vs. 5.6 %; OR, 0.9 [95 % CI, 0.5–1.9]). Within each stage, uptake of smoking cessation treatments increased with higher SOC and with proactive care as compared with usual care.


Mostly male participants limits generalizability. Randomization was not stratified by SOC.


Proactive care increased treatment uptake compared to usual care across all SOC. Proactive care increased smoking cessation among smokers in preparation and contemplation but not in precontemplation. Proactively offering cessation therapies to smokers at all SOC will increase treatment utilization and population-level smoking cessation.


smoking cessation motivation veterans 


Current US smokers overwhelmingly want to quit (68.8 %), and most make at least one quit attempt each year (52.4 %), yet they rarely achieve sustained abstinence (6.2 % per year).1 As a result, the prevalence of smoking in the US has plateaued at approximately 18 % of adults.2 Evidence-based smoking cessation therapies such as medication and counseling significantly increase the success of quit attempts,3,4 but these therapies are underutilized.1,5 Current models of care for tobacco cessation treatment rely on highly motivated smokers to initiate therapy (e.g., by calling state telephone quitlines) or on clinical providers to offer therapy. The US Clinical Practice Guideline6 instructs providers to offer active therapy only to smokers who are “willing” to quit in the next 30 days. The guideline recommends that smokers who are not ready to quit receive brief motivational interventions (e.g., motivational interviewing) to enhance readiness to quit.

The theoretical justification for evaluating smokers’ readiness to quit prior to offering therapy is rooted in the transtheoretical model (TTM).7 This model describes progression through five stages of change (SOC) (precontemplation, contemplation, and preparation for current smokers; action and maintenance for those who have quit) that correlate with ten processes of behavior change. Hundreds of published validation, population, and intervention studies have evaluated the TTM in the context of tobacco use.8,9 According to the TTM, “action-oriented” interventions such as cessation pharmacotherapy are most effective in the advanced stages.10, 11, 12 Unfortunately, 80 % of U.S. smokers have historically fallen into the precontemplation and contemplation stages.13,14 As motivated smokers have quit in response to public health campaigns and policy initiatives,15 the proportion of smokers in preparation has dropped even further, with levels now at only 9–12 %.16,17 Efforts to help early-stage smokers transition to higher stages through motivational interviewing have produced mixed results.18 As the percentage of smokers in preparation shrinks, the practice of offering active therapy only to those preparing to quit will have diminishing returns.

While the TTM has served as a useful framework for understanding behavior change, it has limitations as the basis for clinical practice guidelines. The TTM systematically underestimates smokers’ motivation to quit,19, 20, 21 as many, if not most, precontemplators and contemplators both want to and try to quit.22 In fact, several interventions have documented successful abstinence among precontemplators and contemplators.23, 24, 25 These results substantiate critiques of the construct validity21,26, 27, 28 and inherent instability of the TTM stages.21,29 Interventions that proactively offer evidence-based smoking cessation therapies to all smokers, regardless of SOC, may provide an opportunity to reduce the prevalence of smoking.30

The Veterans Victory Over Tobacco Study randomized smokers to usual care or to a proactive, population-based tobacco cessation intervention that offered telephone or in-person counseling, as well as access to cessation medications, to smokers regardless of SOC. The primary results revealed a statistically significant higher population-level 6-month prolonged smoking abstinence rate at 1 year for proactive care (13.5 %) compared with usual care (10.9 %, p = 0.02).31 In this secondary analysis, we evaluate the effectiveness of proactive care among smokers at different baseline SOC. Our primary question is whether a proactive outreach intervention will increase prolonged abstinence even among those who say they are not ready to quit. Secondary outcomes include the uptake of cessation therapies and quit attempts by smokers at each SOC.


Study Design and Participants

The Veterans Victory Over Tobacco Study was a pragmatic randomized controlled trial, and was approved by the institutional review boards of all participating sites. Current smokers (aged 18 to 80 years) were identified using the US Department of Veterans Affairs (VA) electronic medical record health factor data set. Participants were recruited from October 2009 to September 2010 from four VA medical centers (New York, NY; Jackson, MS; Tampa, FL: Minneapolis, MN), and follow-up was completed in November 2011. Additional details of the trial design and methods were described previously.31,32


The proactive care intervention comprised proactive outreach (mailed materials followed by telephone outreach) combined with an offer of telephone smoking cessation counseling or referral to in-person counseling. Telephone care included a combination of proactive calls from trained counselors at the Minneapolis VA and facilitated access to smoking cessation pharmacotherapy through the participant’s VA provider. The usual care group did not receive proactive outreach but did have access to smoking cessation services through their local VA and their state telephone quitline.

Data Collection

VA administrative and health care utilization data were obtained from the VA National Patient Care Database. Survey data were collected at baseline and 1-year follow-up.


Nicotine dependence was evaluated at baseline and follow-up using time to first morning cigarette and number of cigarettes per day.33 SOC was assessed at baseline and follow-up with the ten-point Readiness to Quit Ladder (RQL).34 Ladder responses 1 through 10 were categorized into low (1–4), medium (5–6), and high (7–10) levels of readiness that approximate and are referenced hereafter as precontemplation, contemplation, and preparation (adapted from Abrams et al.34).

The primary outcome was self-reported 6-month prolonged abstinence at 1-year follow-up, and was assessed among all participants, regardless of treatment utilization. Secondary outcomes included uptake of smoking cessation therapies and quit attempts measured at baseline and follow-up. The use of behavioral counseling (telephone or in-person) and/or smoking cessation medications from any source (including bupropion, varenicline, and nicotine replacement therapy [NRT]) was self-reported. Medications were also assessed using administrative prescription data. Quit attempts were assessed with the question, “During the past 12 months, how many times have you quit smoking intentionally for 24 hours or longer?”


We used stratified random sampling (by site) to select the study sample and a completely randomized block design to assign participants to the intervention or usual care. Accordingly, our estimations, testing, and modeling procedures are stratified analyses. To compare baseline characteristics across the SOC, the weighted stratified Wald χ2 was used for categorical variables and the weighted stratified F-test was used for continuous variables. The weights were inverses of the sampling proportions from each site. To account for possible intra-block correlations, logistic regression mixed modeling was used to test the effect of SOC on the primary outcome, 6-month prolonged abstinence. All models included the intervention and blocking factor (site). We tested the interaction between SOC and treatment arm with respect to the primary outcome. Randomization was not stratified by SOC, which allowed for potentially imbalanced covariates (both measured and unmeasured) between the two treatment arms within each SOC to occur by chance, and this may have created a biased interaction term. To control for between-group imbalances, we have presented a stratified analysis, comparing the treatment effect within each SOC separately. Imbalanced characteristics at the 0.05 significance level were included in the models as adjusting covariates.

To handle non-response, we hypothesized that this might depend on the unobserved smoking status of the subject; that is, we assumed a not-missing-at-random (NMAR) mechanism. We modeled the joint distribution of abstinence status and response status for the logistic regressions using an expectation–maximization algorithm to find maximum likelihood estimators, as described by Ibrahim and colleagues.35,36 This likelihood-based NMAR method creates two data sets, one that assumes all non-responders are smokers, and another that assumes they are all quitters. Then, through a series of iterative weightings, it produces maximum likelihood estimates. The data analysis for this paper including the macro for likelihood-based NMAR modeling was generated using SAS/STAT software, version 9.2 (SAS Institute Inc., Cary, NC, USA).


Of the 5123 eligible, randomized participants, 3006 provided complete baseline survey data, including the RQL, and thus constitute the sample for this secondary analysis (58.5 % [1473/2519] of those randomized to the proactive care intervention and 58.9 % [1533/2604] of those in usual care). At baseline, 781 smokers were in precontemplation (26.0 %), 1148 were in contemplation (38.2 %), and 1077 were in preparation (35.8 %) (Table 1).
Table 1

Participant Characteristics by Baseline Stage of Change


Total, n

Precontemplation, n (%)*or mean (SD)

Contemplation, n (%) or mean (SD)

Preparation, n (%) or mean (SD)

p value

All participants





Treatment group


 Usual care

1533 (51.3)

396 (50.6)

585 (50.7)

552 (52.5)


 Proactive care

1473 (48.7)

385 (49.5)

563 (49.2)

525 (47.5)

Demographic characteristics:

 Age (years)

57.7 (10.6)

59.4 (10.3)

57.0 (10.7)

57.3 (10.5)





1852 (67.2)

543 (74.4)

737 (70.0)

572 (58.4)



774 (22.2)

154 (16.4)

280 (20.2)

340 (29.0)


85 (4.5)

41 (4.2)

59 (3.6)

85 (5.8)


95 (6.1)

43 (5.1)

72 (6.2)

80 (6.8)




2838 (94.4)

741 (94.9)

1080 (94.2)

1017 (94.1)


 Marital status



1460 (50.0)

337 (44.8)

602 (53.6)

521 (50.0)


Socioeconomic status:

 Income ($)


   < 10,000

511 (17.0)

123 (16.1)

185 (16.0)

203 (18.9)



879 (30.8)

238 (32.8)

307 (28.1)

334 (32.4)


841 (30.5)

841 (29.7)

207 (30.4)

323 (31.3)

   ≥ 40,001

593 (21.6)

155 (21.4)

266 (25.5)

172 (17.4)

Social and environmental pressures:

 Home smoking rules


  Not allowed anywhere

1116 (41.1)

237 (33.3)

406 (39.8)

473 (48.6)


  Allowed some places/times

602 (20.7)

142 (19.2)

219 (20.0)

241 (22.3)

  Allowed anywhere

1087 (38.2)

354 (47.5)

438 (40.2)

295 (28.7)

 Friends who smoke



454 (16.2)

116 (15.8)

171 (16.2)

167 (16.5)


   < half

809 (28.7)

185 (24.6)

296 (27.9)

328 (32.7)

  About half

614 (22.2)

163 (22.3)

238 (22.7)

213 (21.7)

   > half

530 (19.4)

134 (18.8)

217 (21.0)

179 (18.0)


384 (13.6)

130 (18.6)

135 (12.2)

119 (11.2)

 People important to me want me to quit smoking

  Strongly disagree to neutral

580 (21.6)

267 (37.8)

188 (17.9)

125 (13.2)


  Somewhat agree

628 (22.8)

196 (26.7)

234 (23.1)

198 (19.3)

  Strongly agree

1569 (55.6)

263 (35.5)

635 (59.0)

671 (67.5)

Smoking behaviors:

 Cigarettes per day


   ≤ 10

1018 (31.3)

211 (24.7)

290 (22.3)

517 (46.7)



1286 (45.0)

341 (46.3)

547 (49.5)

398 (38.9)

   ≥ 21

652 (23.7)

213 (29.0)

301 (28.3)

138 (14.4)

 Time to first cigarette, min


   ≥ 31

809 (25.8)

185 (23.2)

249 (20.7)

375 (33.6)



1535 (52.6)

402 (52.2)

615 (55.1)

518 (50.1)

   < 5

638 (21.6)

188 (24.6)

278 (24.2)

172 (16.3)

 Quit in past 12 months



1673 (54.4)

181 (22.4)

626 (53.2)

866 (80.6)


 Longest quit length


  Never quit

255 (8.3)

128 (16.3)

72 (6.1)

55 (4.7)


   < 1 month

824 (27.1)

230 (29.5)

334 (27.9)

260 (24.2)

  1–6 months

809 (27.2)

187 (24.4)

309 (27.5)

313 (28.9)

   > 6 months

1092 (37.5)

225 (29.8)

426 (38.5)

441 (42.2)

* Observed count (weighted column proportion)

Within precontemplation and contemplation, observed baseline characteristics were balanced across treatment groups (Tables 3 and 4, available online). However, for the preparation group, male gender and level of agreement with the statement “People important to me want me to quit smoking” were not balanced across treatment groups (Table 5, available online). These imbalanced variables were included in the complete case and the NMAR models as adjusting covariates.

Primary Outcome: 6-Month Prolonged Abstinence (Table 2)

Table 2

Primary Outcome: 6-Month Prolonged Abstinence by Baseline Stage of Change and Treatment Arm

Baseline stage of change

Participants, n (%)*

Odds ratio (95 % CI)

Complete case modeln = 2351

Odds ratio (95 % CI)

NMAR model§n = 3006

Usual care, n = 1236

Proactive care, n = 1115


18 (5.6 %)

15 (5.3 %)

0.9 (0.5, 1.9)

1.2 (0.8, 1.8)


31 (6.5 %)

48 (11.0 %)

1.8 (1.1, 2.8)

1.8 (1.3, 2.4)


60 (13.1 %)

82 (21.1 %)

1.8 (1.2, 2.6)

1.6 (1.4, 2.0)

* Observed count (weighted column proportion)

† Usual care is the reference group

‡ Among follow-up survey respondents

§ Likelihood-based NMAR (not-missing-at-random) model accounting for non-response

Six-month prolonged abstinence at 1 year varied by baseline SOC (5.4 % for precontemplators, 8.6 % for contemplators, and 17.1 % for preparers [p < 0.001]). The overall interaction between SOC and treatment arm was not statistically significant (p = 0.30). Among smokers in preparation, those randomized to the proactive intervention were more likely to quit than those in usual care (21.1 % vs 13.1 %, respectively, p = 0.003). Logistic regression mixed modeling analysis, taking into account treatment arm and facility as well as the adjusting covariates described above, found a significant effect of proactive care compared with usual care among preparers (OR, 1.8 [95 % CI, 1.2–2.6]). Similarly, smokers in contemplation who were randomized to the proactive intervention were more likely to quit than those in usual care (11.0 % vs 6.5 %, p = 0.018; OR, 1.8, [95 % CI, 1.1–2.8]).). Smokers in precontemplation quit at similar rates in the two treatment arms (5.3 % vs 5.6 %, p = 0.85; OR, 0.9, [95 % CI, 0.5–1.9]). Analyses accounting for nonresponse using likelihood-based NMAR models showed a similar effect of the proactive care intervention on prolonged abstinence at each SOC (Table 2). Of the 254 study participants who achieved 6-month prolonged abstinence, 55.6 % began the study in preparation, while 44.4 % were not ready to quit at baseline (12.5 % began in precontemplation and 31.9 % in contemplation).

Secondary Outcomes

Uptake of Smoking Cessation Therapies (Fig. 1)

Figure 1

Engagement with smoking cessation therapies by baseline stage of change and treatment arm. PC = precontemplation, C = contemplation, P = preparation, ns = not significant, TC = telephone counseling, C&Rx = counseling & medication, VA Rx = VA-prescribed medication. * 95 % confidence interval for odds ratio does not contain 1.

Smokers at all SOC who were randomized to proactive care engaged in telephone counseling at significantly higher rates than usual-care smokers (7.4 vs. 0.6 % for precontemplation; 16.6 vs 2.7 % for contemplation; 18.8 vs. 3.1 % for preparation) and reported combined therapy with counseling and cessation medication at significantly higher rates than usual care smokers (6.0 vs. 1.5 % for precontemplation; 14.1 vs. 5.7 % for contemplation; 20.7 vs 8.4 % for preparation). Smokers in all SOC who received proactive care were more likely than usual care participants to be prescribed cessation medications through the VA, though this difference reached statistical significance only for contemplation and preparation (20.2 vs. 16.1 % for precontemplation [NS]; 40.9 vs. 33.3 % for contemplation; 44.9 vs. 37.4 % for preparation). Study participants reported using in-person counseling or attending VA smoking cessation clinics at low rates that were not significantly different by study arm or by baseline SOC.

Quit Attempts

Baseline SOC predicted the likelihood of making a quit attempt during the study period. Overall, 31.3 % of precontemplators, 55.6 % of contemplators, and 73.5 % of preparers reported making at least one 24-hour quit attempt during the study follow-up period. There was no significant difference in quit attempts between proactive and usual care.


This proactive population-based smoking cessation intervention included smokers at all stages of change (SOC), and increased long-term prolonged abstinence for smokers in both preparation and contemplation. Smokers in precontemplation did not quit at higher rates in response to proactive outreach, but they were more likely to try evidence-based cessation interventions, including telephone counseling and combined counseling and pharmacotherapy. Proactively offering evidence-based cessation therapies to all smokers led to increased therapeutic engagement and higher long-term population-level quit rates.

Our assessment of an overall interaction between SOC and treatment group revealed no statistically significant difference among SOC subgroups with respect to the intervention. Interaction tests are often underpowered and may be biased when the study is not designed to detect these subgroup effects and randomization is not stratified by subgroup. Thus, we presented additional stratified analyses demonstrating the effect of proactive outreach on smokers at each baseline stage. Among highly motivated smokers (preparation), 73.5 % of whom made at least one quit attempt during follow-up, proactive outreach increased the likelihood of quitting successfully by 50 % (21.1 % vs 13.1 %). Though proactive outreach targets less motivated smokers,37 we found that even highly motivated smokers benefited from proactive outreach through increased uptake of cessation therapies.

Proactive outreach to contemplators appeared to increase cessation by helping smokers overcome high nicotine dependence through the use of evidence-based therapies. Contemplators had attempted to quit in the past at rates similar to preparers, but had much higher levels of nicotine dependence (Table 1). A history of past quit attempts is a predictor of future attempts, but nicotine dependence levels predict the success of those attempts.38,39 Increased therapeutic engagement by contemplators resulted in more successful quit attempts. Our finding that treatment engagement was associated with cessation (OR 1.55 [95 % CI 1.06–2.28] for use of combined therapy) supports this proposed mechanism.

Although proactive outreach increased treatment engagement among precontemplators, we did not observe a difference in smoking cessation rates. It may be that proactive outreach that offers standard cessation therapies is ineffective for precontemplators, who face greater barriers to quitting40 and may require tailored or high-intensity therapy.23 Alternatively, our analysis may have been underpowered to show a difference in cessation among precontemplators, given the smaller size of the subgroup and lower baseline quit rates. Further research is needed for a definitive answer to this question. We found no evidence that the proactive intervention increased unsuccessful quit attempts among precontemplators (31.4 % of precontemplators in usual care and 31.3 % in proactive care made at least one quit attempt during follow-up [p = 0.98]), and thus have no reason to believe that proactive care poses harm to precontemplators.

Our results replicate and extend prior research that has evaluated population-based smoking cessation interventions for smokers at all SOC. Since 1995, when Curry and colleagues first demonstrated the potential effectiveness of telephone-based interventions with non-volunteer smokers at all SOC,25 dozens of telephone-based trials in various populations have supported this proactive approach. However, most have measured only point-prevalent abstinence and/or found short-term (6–9-month follow-up) effects.37,41,42 In contrast, our proactive care intervention achieved prolonged abstinence at long-term (12-month) follow-up among both preparers and contemplators. One reason for this robust effect may be that we combined population-based outreach (using electronic health technology to identify current smokers and to offer telephone-based care) with individual care management (linking care to VA providers to facilitate pharmacotherapy). Smokers in proactive care were much more likely to use combined counseling and pharmacotherapy (Fig. 1), which has been shown to be highly effective.4,6

While earlier telephone counseling studies have included smokers at all SOC, those studies did not provide information as to whether smokers at lower SOC benefitted from the interventions or merely diluted the population-level treatment effect. In 2015, Haas and colleagues43 addressed this deficiency, reporting that their telephone-based intervention using interactive voice response increased abstinence both among those planning to quit within the next 30 days and among those with no plans to quit. Our report provides additional information on the magnitude of the treatment effect on less motivated smokers and divides less motivated smokers into subgroups of precontemplators and contemplators.

Interest in treating smokers at all SOC has grown over the past decade. In 2005, Pisinger and colleagues first reported the success of the Inter99 trial, which found that a high-intensity intervention could engage less motivated smokers and increase rates of abstinence.23,44 Several editorials, citing the success of Inter99, have questioned current guideline recommendations to assess motivation to quit prior to offering cessation therapy.26,45 Aveyard and colleagues conducted a systematic review and meta-analysis of brief physician interventions among smokers at all motivation levels and concluded that combining physician advice to quit with the offer of cessation support motivated an additional 40–60 % of smokers to attempt to quit, compared with advice alone.30 The authors suggested that offering assistance in quitting to smokers at all SOC may be effective because the offer itself increases confidence in success. To explain why less motivated smokers often respond to offers of cessation therapy, others have advanced an alternative theory of smoking cessation based in “catastrophe theory,” which posits that motivational tension fluctuates, and small triggers can induce apparently spontaneous quit attempts.46,47

Carpenter and colleagues subsequently reported that among unmotivated smokers, NRT sampling was more successful for inducing quit attempts and short-term cessation than practice quit attempts alone.48 Two additional small studies compared the offer of NRT to usual care and found promising short-term results regardless of motivation.49,50 After more than a decade of small studies, meta-analyses, and editorials, we now report on the largest low-intensity, pragmatic, proactive care intervention with long-term outcomes among smokers who were not planning to quit at baseline.

Limitations include a study population of mostly older male US veteran smokers, which may limit generalizability to other populations of smokers. Our study, a non-pre-specified subgroup analysis, is restricted to those participants who completed the baseline survey questions that established SOC, and thus this sample may be more engaged than the overall population. Follow-up data availability is limited to an even smaller group. We address the potential for response bias in follow-up data by including a likelihood-based NMAR model analysis. In the primary analysis,31 we also addressed possible differential non-response between treatment groups, and found that taking into account non-response bias did not substantially alter the results. Additional limitations result from inconsistencies in operationalizing the TTM across the literature, making it difficult to compare our SOC with those in other studies.9

This large, pragmatic randomized trial of a telephone-based intervention demonstrated increased uptake of smoking cessation therapies and prolonged abstinence at 1 year both for smokers who were already planning to quit and for those who were not. Similar to the results of prior studies,23,25 we found that among participants who quit successfully, nearly half began the study stating that they were not ready to quit. Restricting therapy to only those in the preparation stage would exclude 64 % of the smokers in our sample, and 44 % of those who quit. Our results add to the growing body of evidence that smoking cessation therapy should be proactively offered to all smokers, regardless of stated plans to quit.



Additional Contributors



This study was funded by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Health Services Research and Development (IAB-05-303), and was registered on (NCT00608426). This work was supported in part by Career Development Award (Japuntich) no. 1IK2CX000918-01A1 from the Clinical Sciences Research and Development Service of the US Department of Veterans Affairs Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs or the US government.

Prior Presentations

Preliminary results were presented at the Society for Research on Nicotine and Tobacco's SRNT Europe 16th Annual Congress, 2015 Sep 10–12, Maastricht, Netherlands.

Compliance with Ethical Standards

Conflict of Interest

All study authors declare that they have no conflict of interest.


  1. 1.
    Centers for Disease Control and Prevention. Quitting smoking among adults—United States 2001–2010. 2011:1513–1519.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults—United States, 2005–2013. 2014:1108–1112.Google Scholar
  3. 3.
    Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10, CD008286.PubMedGoogle Scholar
  4. 4.
    Kotz D, Brown J, West R. ‘Real-world’ effectiveness of smoking cessation treatments: a population study. Addiction. 2014;109(3):491–499.CrossRefPubMedGoogle Scholar
  5. 5.
    Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–111.CrossRefPubMedGoogle Scholar
  6. 6.
    Fiore M, Jaen C, Baker T, Bailey W, Benowitz N, Curry S, et al. Treating Tobacco use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.Google Scholar
  7. 7.
    Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract Train. 1982;19:276–288.CrossRefGoogle Scholar
  8. 8.
    Spencer L, Pagell F, Hallion M, Adams T. Applying the transtheoretical model to tobacco cessation and prevention: a review of literature. Am J Health Promot. 2002;17(1):7–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Cahill K, Lancaster T, Green N. Stage-based interventions for smoking cessation. Cochrane Database Syst Rev. 2010;11, CD004492.PubMedGoogle Scholar
  10. 10.
    Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–395.CrossRefPubMedGoogle Scholar
  11. 11.
    DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol. 1991;59(2):295–304.CrossRefPubMedGoogle Scholar
  12. 12.
    Prochaska JO. Flaws in the theory or flaws in the study: a commentary on "the effect of transtheoretical model based interventions on smoking cessation". Soc Sci Med. 2009;68(3):404–406.CrossRefPubMedGoogle Scholar
  13. 13.
    Velicer WF, Fava JL, Prochaska JO, Abrams DB, Emmons KM, Pierce JP. Distribution of smokers by stage in three representative samples. Prev Med. 1995;24(4):401–411.CrossRefPubMedGoogle Scholar
  14. 14.
    Etter JF, Perneger TV, Ronchi A. Distributions of smokers by stage: international comparison and association with smoking prevalence. Prev Med. 1997;26(4):580–585.CrossRefPubMedGoogle Scholar
  15. 15.
    Warner KE, Burns DM. Hardening and the hard-core smoker: concepts, evidence, and implications. Nicotine Tob Res. 2003;5(1):37–48.CrossRefPubMedGoogle Scholar
  16. 16.
    Wewers ME, Stillman FA, Hartman AM, Shopland DR. Distribution of daily smokers by stage of change: current population survey results. Prev Med. 2003;36(6):710–720.CrossRefPubMedGoogle Scholar
  17. 17.
    ITC Project. ITC United States National Report. Findings from the Wave 1 to 8 Surveys (2002–2011). Waterloo (ON): University of Waterloo; and Charleston (SC): Medical University of South Carolina: 2014.Google Scholar
  18. 18.
    Lundahl BW, Kunz C, Brownell C, Tollefson D, Burke BL. A meta-analysis of motivational interviewing: twenty-five years of empirical studies. Res Soc Work Pract. 2010;20(2):137–160.CrossRefGoogle Scholar
  19. 19.
    Sciamanna C, Hoch J, Duke GC, Fogle M, Ford D. Comparison of five measures of motivation to quit smoking among a sample of hospitalized smokers. J Gen Intern Med. 2000;15(1):16–23.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Herzog TA, Abrams DB, Emmons KM, Linnan L. Predicting increases in readiness to quit smoking: a prospective analysis using the contemplation ladder. Psychol Health. 2000;15(3):369–381.CrossRefGoogle Scholar
  21. 21.
    Etter JF, Sutton S. Assessing ‘stage of change’ in current and former smokers. Addiction. 2002;97:1171–1182.CrossRefPubMedGoogle Scholar
  22. 22.
    Herzog TA, Blagg CO. Are most precontemplators contemplating smoking cessation? Assessing the validity of the stages of change. Health Psychol. 2007;26(2):222–231.CrossRefPubMedGoogle Scholar
  23. 23.
    Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev Med. 2005;40(3):278–284.PubMedGoogle Scholar
  24. 24.
    Tzelepis F, Paul CL, Walsh RA, Wiggers J, Duncan SL, Knight J. Predictors of abstinence among smokers recruited actively to quitline support. Addiction. 2013;108(1):181–185.CrossRefPubMedGoogle Scholar
  25. 25.
    Curry S, McBride C, Grothaus L, Louie D, Wagner E. A randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin Psychol. 1995;63(6):1005–1014.CrossRefPubMedGoogle Scholar
  26. 26.
    West R. Time for a change: putting the transtheoretical (stages of change) model to rest. Addiction. 2005;100(8):1036–1039.CrossRefPubMedGoogle Scholar
  27. 27.
    Kraft P, Sutton S, Reynolds H. The transtheoretical model of behavior change: are the stages qualitatively different? Psychol Health. 1999;14:433–450.CrossRefGoogle Scholar
  28. 28.
    Herzog TA. Analyzing the transtheoretical model using the framework of Weinstein, Rothman, and Sutton (1998): the example of smoking cessation. Health Psychol. 2008;27(5):548–556.CrossRefPubMedGoogle Scholar
  29. 29.
    Hughes JR, Keely JP, Fagerstrom KO, Callas PW. Intentions to quit smoking change over short periods of time. Addict Behav. 2005;30(4):653–662.CrossRefPubMedGoogle Scholar
  30. 30.
    Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012;107:1066–1073.CrossRefPubMedGoogle Scholar
  31. 31.
    Fu SS, van Ryn M, Sherman SE. Proactive tobacco treatment and population-level cessation: a pragmatic randomized clinical trial. JAMA Intern Med. 2014;174(5):671–677.CrossRefPubMedGoogle Scholar
  32. 32.
    Fu SS, van Ryn M, Sherman SE, Burgess DJ, Noorbaloochi S, Clothier B, et al. Population-based tobacco treatment: study design of a randomized controlled trial. BMC Public Health. 2012;12:159.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chabrol H, Niezborala M, Chastan E, de Leon J. Comparison of the heavy smoking index and of the fagerstrom test for nicotine dependence in a sample of 749 cigarette smokers. Addict Behav. 2005;30(7):1474–1477.CrossRefPubMedGoogle Scholar
  34. 34.
    Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM. The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. New York: The Guilford Press; 2003.Google Scholar
  35. 35.
    Ibrahim J, Chen M, Lipsitz S. Missing responses in generalised linear mixed models when the missing data mechanism is nonignorable. Biometrika. 2001;88(2):551–564.CrossRefGoogle Scholar
  36. 36.
    Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. New Jersey: Wiley; 2003.CrossRefGoogle Scholar
  37. 37.
    Tzelepis F, Paul CL, Walsh RA, McElduff P, Knight J. Proactive telephone counseling for smoking cessation: meta-analyses by recruitment channel and methodological quality. J Natl Cancer Inst. 2011;103(12):922–941.CrossRefPubMedGoogle Scholar
  38. 38.
    Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction. 2011;106(12):2110–2121.CrossRefPubMedGoogle Scholar
  39. 39.
    Hyland A, Borland R, Li Q, Yong HH, McNeill A, Fong GT, et al. Individual-level predictors of cessation behaviours among participants in the international tobacco control (ITC) four country survey. Tob Control. 2006;15(Suppl 3):iii83–iii94.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Dijkstra A, De VH. Subtypes of precontemplating smokers defined by different long-term plans to change their smoking behavior. Health Educ Res. 2000;15(4):423–434.CrossRefPubMedGoogle Scholar
  41. 41.
    Tzelepis F, Paul CL, Wiggers J, Walsh RA, Knight J, Duncan SL, et al. A randomised controlled trial of proactive telephone counselling on cold-called smokers' cessation rates. Tob Control. 2011;20(1):40–46.CrossRefPubMedGoogle Scholar
  42. 42.
    Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2013;8, CD002850.PubMedGoogle Scholar
  43. 43.
    Haas JS, Linder JA, Park ER. Proactive tobacco cessation outreach to smokers of low socioeconomic status: a randomized clinical trial. JAMA Intern Med. 2015;175(2):218–226.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pisinger C, Vestbo J, Borch-Johnsen K, Thomsen T, Jorgensen T. Acceptance of the smoking cessation intervention in a large population-based study: The Inter99 study. Scand J Public Health. 2005;33(2):138–145.CrossRefPubMedGoogle Scholar
  45. 45.
    Richter KP, Ellerbeck EF. It's time to change the default for tobacco treatment. Addiction. 2015;110(3):381–386.CrossRefPubMedGoogle Scholar
  46. 46.
    Brown C. Chaos and Catastrophic Theories: Quantitative Applications in the Social Sciences. London: Sage; 1995.CrossRefGoogle Scholar
  47. 47.
    West R, Sohal T. "Catastrophic" pathways to smoking cessation: findings from national survey. BMJ. 2006;332(7539):458–460.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med. 2011;171(21):1901–1907.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cropsey KL, Hendricks PS, Jardin B, Clark CB, Katiyar N, Willig J, et al. A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in non-treatment seeking smokers with HIV. Addict Behav. 2013;38(10):2541–2546.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Jardin BF, Cropsey KL, Wahlquist AE, Gray KM, Silvestri GA, Cummings KM, et al. Evaluating the effect of access to free medication to quit smoking: a clinical trial testing the role of motivation. Nicotine Tob Res. 2014;16(7):992–999.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Elisheva R. Danan
    • 1
    • 2
  • Anne M. Joseph
    • 2
  • Scott E. Sherman
    • 3
    • 4
  • Diana J. Burgess
    • 1
    • 2
  • Siamak Noorbaloochi
    • 1
    • 2
  • Barbara Clothier
    • 1
  • Sandra J. Japuntich
    • 5
    • 6
  • Brent C. Taylor
    • 1
    • 2
  • Steven S. Fu
    • 1
    • 2
  1. 1.VA HSR&D Center for Chronic Disease Outcomes ResearchMinneapolis VA Health Care SystemMinneapolisUSA
  2. 2.Department of MedicineUniversity of Minnesota Medical SchoolMinneapolisUSA
  3. 3.VA New York Harbor Healthcare SystemNew York CityUSA
  4. 4.Department of Population HealthNew York University School of MedicineNew York CityUSA
  5. 5.National Center for PTSDVA Boston Healthcare SystemBostonUSA
  6. 6.Department of PsychiatryBoston University School of MedicineBostonUSA

Personalised recommendations